Sep 06, 2023 / 02:30PM GMT
Yigal Dov Nochomovitz - Citigroup Inc., Research Division - Director
Great. The next panel is ADC antibody drug conjugates. I'm Yigal Nochomovitz. I'm one of the biotech analysts here. I cover all 3 of these companies, MacroGenics, Zai Lab and Zymeworks. So Scott Koenig, CEO of MacroGenics, welcome; Rafael Amado, President, Head of Global Oncology and R&D at Zai Lab; and Paul Moore, CSO at Zymeworks. So thank you all very much for being here. I appreciate it.
Just to start out, why don't we just do a quick lightning around. Give us a very quick introduction to the company and then with a specific focus on your ADC programs and just some of the very key highlights and then we can go from there.
Scott Koenig - MacroGenics, Inc. - President, CEO & Director
Terrific. Scott Koenig. So MacroGenics is 23 years in operation. We've been focused on developing immune-based therapeutics from the inception. We have 3 validated proprietary platforms, Fc-engineered molecules, bispecifics, which we call DART molecules and then ADC program. The company has been
Zymeworks Inc at Citi BioPharma Conference Transcript
Sep 06, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers